 Gary Luckasen
Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Potassium Channels, Inwardly Rectifying | 9 | 2020 | 47 | 1.010 |
Why?
| | Vasodilation | 13 | 2021 | 516 | 0.830 |
Why?
| | Air Pollution, Indoor | 5 | 2020 | 184 | 0.680 |
Why?
| | Hand Strength | 8 | 2022 | 132 | 0.600 |
Why?
| | Sodium-Potassium-Exchanging ATPase | 7 | 2018 | 55 | 0.560 |
Why?
| | Muscle, Skeletal | 12 | 2022 | 1753 | 0.530 |
Why?
| | Household Articles | 3 | 2020 | 28 | 0.480 |
Why?
| | Forearm | 13 | 2022 | 139 | 0.480 |
Why?
| | Hyperemia | 4 | 2018 | 49 | 0.480 |
Why?
| | Adenosine Triphosphate | 6 | 2022 | 493 | 0.480 |
Why?
| | Regional Blood Flow | 13 | 2022 | 498 | 0.440 |
Why?
| | Muscle Contraction | 7 | 2020 | 435 | 0.430 |
Why?
| | Cooking | 5 | 2020 | 66 | 0.420 |
Why?
| | Hypoxia | 6 | 2022 | 1164 | 0.380 |
Why?
| | Air Pollution | 3 | 2020 | 322 | 0.370 |
Why?
| | Smoke | 4 | 2020 | 148 | 0.360 |
Why?
| | Exercise | 10 | 2018 | 2103 | 0.350 |
Why?
| | Vasoconstriction | 7 | 2021 | 219 | 0.330 |
Why?
| | Prostaglandins | 5 | 2017 | 101 | 0.300 |
Why?
| | Sympathetic Nervous System | 4 | 2020 | 174 | 0.270 |
Why?
| | Acetylcholine | 4 | 2021 | 203 | 0.250 |
Why?
| | Young Adult | 23 | 2022 | 13673 | 0.240 |
Why?
| | Endothelium, Vascular | 5 | 2021 | 951 | 0.230 |
Why?
| | Nitric Oxide | 6 | 2017 | 900 | 0.230 |
Why?
| | Adipose Tissue, Brown | 2 | 2016 | 56 | 0.220 |
Why?
| | Brachial Artery | 5 | 2020 | 204 | 0.210 |
Why?
| | Physical Endurance | 4 | 2019 | 275 | 0.200 |
Why?
| | Glucosides | 2 | 2020 | 49 | 0.190 |
Why?
| | Benzhydryl Compounds | 2 | 2020 | 75 | 0.190 |
Why?
| | Pulse Wave Analysis | 2 | 2020 | 237 | 0.190 |
Why?
| | Adult | 30 | 2022 | 39181 | 0.170 |
Why?
| | Potassium | 3 | 2018 | 148 | 0.170 |
Why?
| | Carotid Intima-Media Thickness | 1 | 2020 | 68 | 0.170 |
Why?
| | Directive Counseling | 1 | 2020 | 47 | 0.160 |
Why?
| | Particulate Matter | 2 | 2020 | 330 | 0.160 |
Why?
| | Diet, Reducing | 1 | 2020 | 91 | 0.160 |
Why?
| | Blood Pressure | 5 | 2019 | 1748 | 0.150 |
Why?
| | Nitroprusside | 4 | 2021 | 72 | 0.150 |
Why?
| | Recommended Dietary Allowances | 1 | 2018 | 19 | 0.150 |
Why?
| | Weight Reduction Programs | 1 | 2020 | 117 | 0.150 |
Why?
| | Adrenergic alpha-Antagonists | 2 | 2017 | 34 | 0.140 |
Why?
| | Sympatholytics | 2 | 2015 | 13 | 0.140 |
Why?
| | Clonidine | 2 | 2015 | 34 | 0.140 |
Why?
| | Micronutrients | 1 | 2018 | 92 | 0.140 |
Why?
| | Beta vulgaris | 1 | 2018 | 13 | 0.140 |
Why?
| | Male | 31 | 2021 | 69789 | 0.140 |
Why?
| | Performance-Enhancing Substances | 1 | 2017 | 10 | 0.130 |
Why?
| | Nitrates | 1 | 2018 | 97 | 0.130 |
Why?
| | Vasodilator Agents | 5 | 2018 | 330 | 0.130 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 2016 | 21 | 0.130 |
Why?
| | Hemodynamics | 3 | 2022 | 1100 | 0.130 |
Why?
| | Cyclooxygenase Inhibitors | 5 | 2014 | 83 | 0.120 |
Why?
| | Methazolamide | 1 | 2015 | 5 | 0.120 |
Why?
| | Aminophylline | 1 | 2015 | 12 | 0.120 |
Why?
| | Athletic Performance | 1 | 2017 | 81 | 0.120 |
Why?
| | Vascular Stiffness | 1 | 2020 | 449 | 0.120 |
Why?
| | Dengue Vaccines | 1 | 2015 | 11 | 0.120 |
Why?
| | Humans | 38 | 2022 | 141197 | 0.120 |
Why?
| | Nutritional Status | 1 | 2018 | 362 | 0.120 |
Why?
| | Barium Compounds | 4 | 2018 | 12 | 0.120 |
Why?
| | Altitude | 2 | 2017 | 475 | 0.120 |
Why?
| | Air Pollutants | 1 | 2020 | 430 | 0.120 |
Why?
| | Receptors, Adrenergic, alpha-1 | 1 | 2015 | 45 | 0.110 |
Why?
| | Potassium Channel Blockers | 4 | 2018 | 47 | 0.110 |
Why?
| | Overweight | 1 | 2020 | 587 | 0.110 |
Why?
| | Adaptation, Physiological | 1 | 2019 | 560 | 0.110 |
Why?
| | Lipid Metabolism | 1 | 2018 | 528 | 0.110 |
Why?
| | Phentolamine | 1 | 2014 | 18 | 0.110 |
Why?
| | Exercise Therapy | 1 | 2019 | 447 | 0.110 |
Why?
| | Chlorides | 4 | 2018 | 138 | 0.110 |
Why?
| | Glucose | 2 | 2020 | 1041 | 0.110 |
Why?
| | Dengue | 1 | 2015 | 83 | 0.110 |
Why?
| | Positron-Emission Tomography | 1 | 2016 | 310 | 0.110 |
Why?
| | Immunization Schedule | 1 | 2015 | 203 | 0.110 |
Why?
| | Adipose Tissue, White | 1 | 2014 | 43 | 0.100 |
Why?
| | Female | 23 | 2021 | 75522 | 0.100 |
Why?
| | Metformin | 1 | 2017 | 333 | 0.100 |
Why?
| | Fibronectins | 1 | 2014 | 135 | 0.100 |
Why?
| | Spinal Cord | 1 | 2016 | 373 | 0.100 |
Why?
| | Metabolomics | 1 | 2018 | 705 | 0.100 |
Why?
| | Healthy Volunteers | 3 | 2019 | 214 | 0.090 |
Why?
| | Potassium Chloride | 3 | 2018 | 42 | 0.090 |
Why?
| | Running | 1 | 2014 | 232 | 0.090 |
Why?
| | Lower Body Negative Pressure | 3 | 1999 | 26 | 0.080 |
Why?
| | Ouabain | 3 | 2015 | 18 | 0.080 |
Why?
| | Volunteers | 2 | 2020 | 40 | 0.080 |
Why?
| | Ketorolac | 3 | 2015 | 25 | 0.080 |
Why?
| | Double-Blind Method | 3 | 2020 | 1983 | 0.080 |
Why?
| | omega-N-Methylarginine | 3 | 2015 | 31 | 0.080 |
Why?
| | Insulin Resistance | 2 | 2019 | 1225 | 0.070 |
Why?
| | Nitric Oxide Synthase | 3 | 2013 | 242 | 0.070 |
Why?
| | Aging | 2 | 2017 | 1893 | 0.070 |
Why?
| | Triglycerides | 2 | 2020 | 514 | 0.060 |
Why?
| | Lung | 1 | 2020 | 4134 | 0.060 |
Why?
| | Obesity | 1 | 2020 | 3004 | 0.060 |
Why?
| | Vascular Resistance | 4 | 2014 | 364 | 0.060 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2019 | 2526 | 0.060 |
Why?
| | Brain | 1 | 2016 | 2858 | 0.050 |
Why?
| | Exercise Test | 2 | 2015 | 625 | 0.050 |
Why?
| | Middle Aged | 7 | 2020 | 34438 | 0.050 |
Why?
| | Syncope | 2 | 1999 | 56 | 0.050 |
Why?
| | Adrenergic Agents | 1 | 2021 | 7 | 0.040 |
Why?
| | rho-Associated Kinases | 1 | 2022 | 84 | 0.040 |
Why?
| | Maximal Midexpiratory Flow Rate | 1 | 2020 | 4 | 0.040 |
Why?
| | Catecholamines | 2 | 2017 | 93 | 0.040 |
Why?
| | Body Composition | 2 | 2017 | 701 | 0.040 |
Why?
| | Lipoproteins, VLDL | 1 | 2020 | 19 | 0.040 |
Why?
| | Body Fat Distribution | 1 | 2020 | 48 | 0.040 |
Why?
| | Cross-Over Studies | 1 | 2022 | 578 | 0.040 |
Why?
| | Endothelium | 1 | 2020 | 127 | 0.040 |
Why?
| | Hypotension, Orthostatic | 1 | 1999 | 10 | 0.040 |
Why?
| | Sodium-Glucose Transporter 2 | 1 | 2019 | 26 | 0.040 |
Why?
| | Spirometry | 1 | 2020 | 264 | 0.040 |
Why?
| | Aged | 5 | 2020 | 24576 | 0.040 |
Why?
| | Aerospace Medicine | 1 | 1999 | 33 | 0.040 |
Why?
| | Cardiography, Impedance | 1 | 1999 | 9 | 0.040 |
Why?
| | Diet, Sodium-Restricted | 1 | 1999 | 38 | 0.040 |
Why?
| | Vital Capacity | 1 | 2020 | 312 | 0.040 |
Why?
| | Echocardiography | 2 | 1999 | 643 | 0.040 |
Why?
| | Stroke Volume | 2 | 1999 | 587 | 0.040 |
Why?
| | Myocardial Reperfusion | 1 | 1999 | 52 | 0.040 |
Why?
| | Forced Expiratory Volume | 1 | 2020 | 489 | 0.040 |
Why?
| | Muscle Fibers, Skeletal | 1 | 2020 | 216 | 0.040 |
Why?
| | Hospitals, Community | 1 | 1999 | 59 | 0.040 |
Why?
| | Angioplasty, Balloon, Coronary | 1 | 1999 | 141 | 0.040 |
Why?
| | Magnesium | 1 | 2018 | 157 | 0.040 |
Why?
| | Vitamin E | 1 | 2018 | 123 | 0.040 |
Why?
| | Enzyme Inhibitors | 2 | 2012 | 854 | 0.040 |
Why?
| | Biomarkers | 2 | 2020 | 4175 | 0.030 |
Why?
| | Fruit and Vegetable Juices | 1 | 2018 | 17 | 0.030 |
Why?
| | Cholesterol, HDL | 1 | 2018 | 196 | 0.030 |
Why?
| | Plant Roots | 1 | 2018 | 44 | 0.030 |
Why?
| | Nitrites | 1 | 2018 | 89 | 0.030 |
Why?
| | Adolescent | 4 | 2020 | 22007 | 0.030 |
Why?
| | Glycogen | 1 | 2017 | 54 | 0.030 |
Why?
| | Folic Acid | 1 | 2018 | 195 | 0.030 |
Why?
| | Adrenergic alpha-1 Receptor Agonists | 1 | 2016 | 3 | 0.030 |
Why?
| | Athletes | 1 | 2020 | 410 | 0.030 |
Why?
| | Blood Gas Analysis | 1 | 2017 | 83 | 0.030 |
Why?
| | Phenylephrine | 1 | 2016 | 75 | 0.030 |
Why?
| | Cholesterol, LDL | 1 | 2018 | 361 | 0.030 |
Why?
| | Adrenergic beta-Agonists | 1 | 2017 | 98 | 0.030 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2018 | 593 | 0.030 |
Why?
| | Combined Modality Therapy | 1 | 2019 | 1243 | 0.030 |
Why?
| | Vasoconstrictor Agents | 1 | 2016 | 134 | 0.030 |
Why?
| | Risk | 1 | 2018 | 904 | 0.030 |
Why?
| | Blood Glucose | 2 | 2019 | 2269 | 0.030 |
Why?
| | Oxyhemoglobins | 1 | 2015 | 24 | 0.030 |
Why?
| | Lipids | 1 | 2020 | 689 | 0.030 |
Why?
| | Adrenergic beta-Antagonists | 1 | 2017 | 228 | 0.030 |
Why?
| | Heart Rate | 2 | 2015 | 821 | 0.030 |
Why?
| | Propranolol | 1 | 2015 | 45 | 0.030 |
Why?
| | Tandem Mass Spectrometry | 1 | 2018 | 566 | 0.030 |
Why?
| | Injections, Subcutaneous | 1 | 2015 | 165 | 0.030 |
Why?
| | Placebos | 1 | 2015 | 198 | 0.030 |
Why?
| | Vitamin D | 1 | 2018 | 397 | 0.030 |
Why?
| | Heart | 1 | 1999 | 620 | 0.030 |
Why?
| | Analysis of Variance | 2 | 2013 | 1320 | 0.030 |
Why?
| | Vaccines, Attenuated | 1 | 2015 | 130 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2016 | 147 | 0.030 |
Why?
| | Treatment Outcome | 2 | 2020 | 11120 | 0.030 |
Why?
| | Oxygen Consumption | 1 | 2018 | 715 | 0.030 |
Why?
| | NG-Nitroarginine Methyl Ester | 1 | 2014 | 49 | 0.030 |
Why?
| | Cold Temperature | 1 | 2016 | 194 | 0.030 |
Why?
| | Muscle, Smooth, Vascular | 1 | 2017 | 450 | 0.030 |
Why?
| | Physical Conditioning, Human | 1 | 2014 | 40 | 0.030 |
Why?
| | Infusions, Intra-Arterial | 1 | 2013 | 61 | 0.030 |
Why?
| | Nitric Oxide Synthase Type III | 1 | 2014 | 200 | 0.030 |
Why?
| | Adenosine | 1 | 2015 | 244 | 0.030 |
Why?
| | Dietary Supplements | 1 | 2018 | 566 | 0.030 |
Why?
| | Plethysmography | 1 | 2013 | 109 | 0.030 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2015 | 256 | 0.020 |
Why?
| | Microcirculation | 1 | 2013 | 150 | 0.020 |
Why?
| | Fibroblast Growth Factors | 1 | 2014 | 180 | 0.020 |
Why?
| | Drug Therapy, Combination | 1 | 2015 | 1040 | 0.020 |
Why?
| | Calcium | 1 | 2018 | 1187 | 0.020 |
Why?
| | Membrane Potentials | 1 | 2013 | 284 | 0.020 |
Why?
| | Blood Flow Velocity | 1 | 2013 | 412 | 0.020 |
Why?
| | Ketorolac Tromethamine | 1 | 2011 | 4 | 0.020 |
Why?
| | Nitric Oxide Synthase Type I | 1 | 2011 | 29 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 1999 | 1069 | 0.020 |
Why?
| | Arteries | 1 | 2013 | 263 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2382 | 0.020 |
Why?
| | Absorptiometry, Photon | 1 | 2011 | 266 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4073 | 0.020 |
Why?
| | Cardiac Volume | 2 | 1999 | 15 | 0.020 |
Why?
| | Data Interpretation, Statistical | 1 | 2011 | 376 | 0.020 |
Why?
| | Incidence | 1 | 2015 | 2794 | 0.020 |
Why?
| | Sex Characteristics | 1 | 2014 | 788 | 0.020 |
Why?
| | Insulin | 1 | 2019 | 2482 | 0.020 |
Why?
| | Aged, 80 and over | 2 | 2017 | 7856 | 0.020 |
Why?
| | Time Factors | 2 | 2013 | 6956 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2011 | 2064 | 0.020 |
Why?
| | Cardiovascular Diseases | 1 | 2018 | 2087 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2013 | 3588 | 0.010 |
Why?
| | Ventricular Function, Left | 2 | 1999 | 513 | 0.010 |
Why?
| | Signal Transduction | 1 | 2016 | 5144 | 0.010 |
Why?
| | Renin | 1 | 1999 | 36 | 0.010 |
Why?
| | Hematocrit | 1 | 1999 | 104 | 0.010 |
Why?
| | Weightlessness | 1 | 1999 | 48 | 0.010 |
Why?
| | Cardiac Output | 1 | 1999 | 177 | 0.010 |
Why?
| | Child | 1 | 2018 | 22310 | 0.010 |
Why?
| | Sodium | 1 | 1999 | 196 | 0.010 |
Why?
| | Space Flight | 1 | 1999 | 93 | 0.010 |
Why?
| | United States | 1 | 2015 | 15220 | 0.010 |
Why?
| | Posture | 1 | 1999 | 195 | 0.010 |
Why?
| | Bias | 1 | 1999 | 229 | 0.010 |
Why?
| | Coronary Artery Bypass | 1 | 1999 | 243 | 0.010 |
Why?
| | Coronary Angiography | 1 | 1999 | 316 | 0.010 |
Why?
| | Linear Models | 1 | 1999 | 857 | 0.010 |
Why?
| | Reoperation | 1 | 1999 | 588 | 0.010 |
Why?
| | Acute Disease | 1 | 1999 | 1008 | 0.010 |
Why?
| | Survival Rate | 1 | 1999 | 1970 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 1999 | 3348 | 0.010 |
Why?
| | Prospective Studies | 1 | 1999 | 7739 | 0.000 |
Why?
|
|
Luckasen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|